The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pharmacogenetic profiling for oxaliplatin-based adjuvant chemotherapy (CT) benefit in stage II-III colon cancer (CC) patients: A GEMCAD study.
Jaime Feliu
No relevant relationships to disclose
Ana Custodio
No relevant relationships to disclose
Juan Moreno
No relevant relationships to disclose
Jorge Aparicio
No relevant relationships to disclose
Javier Gallego
No relevant relationships to disclose
Ricardo Yaya
No relevant relationships to disclose
Juan Maurel
No relevant relationships to disclose
Carlos Fernandez-Martos
No relevant relationships to disclose
Antonio Sánchez
No relevant relationships to disclose
Ana M Calatrava
No relevant relationships to disclose
Emilio Burgos
No relevant relationships to disclose
Virginia Martinez Marín
No relevant relationships to disclose
Javier De Castro
No relevant relationships to disclose
Jorge Barriuso
No relevant relationships to disclose
Victor Moreno
No relevant relationships to disclose
Nadia Hindi
No relevant relationships to disclose
Rosario Madero
No relevant relationships to disclose
Pablo Lapunzina
No relevant relationships to disclose
Paloma Cejas
No relevant relationships to disclose